|
AU2006227101A1
|
|
Methods for treating or preventing acute myelogenous leukemia
|
|
ZA200410101B
|
|
Compounds usefel for the treatment of cancer, compositions thereof and methods therewith
|
|
EP2065383A1
|
|
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
|
ZA200407150B
|
|
Combination therapy for treating, preventing or managing proliferative disorders and cancer.
|
|
WO2005003301A2
|
|
Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms
|
|
ZA200402765B
|
|
Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis.
|
|
CA2482986A1
|
|
Benzopyranone compounds, compositions thereof, and methods of treatment therewith
|
|
EP1487436A1
|
|
Combination therapy for treating, preventing or managing proliferative disorders and cancers
|
|
AU2002305469A1
|
|
Markers for evaluating estrogenic activity
|
|
US6620838B1
|
|
Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
|
|
US6897231B2
|
|
Indazole derivatives as JNK inhibitors and compositions and methods related thereto
|
|
IL150463D0
|
|
Compounds and methods for modulation of estrogen receptors
|
|
US6677130B1
|
|
Mitogen-activated protein kinase p38-2 and methods of use therefor
|
|
US6593322B1
|
|
Compounds and methods for modulation of estrogen receptors
|
|
WO0116604A1
|
|
Screening for agents modulating tgf-beta cell signaling
|
|
IL148187D0
|
|
Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
|
|
KR20080028516A
|
|
Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
|
|
US6331562B1
|
|
Compounds and methods for modulation of estrogen receptors
|
|
EP1163225A1
|
|
Compounds and methods for modulation of estrogen receptors
|
|
US6291456B1
|
|
Compounds and methods for modulation of estrogen receptors
|
